Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Sees Large Growth in Short Interest

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) was the recipient of a significant increase in short interest in December. As of December 31st, there was short interest totalling 6,000,000 shares, an increase of 6.0% from the December 15th total of 5,660,000 shares. Based on an average trading volume of 250,800 shares, the days-to-cover ratio is presently 23.9 days. Approximately 31.2% of the company’s stock are short sold.

Dianthus Therapeutics Stock Up 4.1 %

Shares of NASDAQ DNTH traded up $0.79 during midday trading on Monday, reaching $20.00. 156,254 shares of the stock were exchanged, compared to its average volume of 199,749. The firm has a market cap of $592 million, a price-to-earnings ratio of -8.00 and a beta of 1.74. Dianthus Therapeutics has a twelve month low of $10.65 and a twelve month high of $33.77. The firm has a 50-day simple moving average of $23.62 and a two-hundred day simple moving average of $26.40.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). The firm had revenue of $2.17 million for the quarter, compared to analyst estimates of $1.07 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. Research analysts expect that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC lifted its position in shares of Dianthus Therapeutics by 9.2% during the 4th quarter. SG Americas Securities LLC now owns 9,653 shares of the company’s stock valued at $210,000 after buying an additional 814 shares in the last quarter. Barclays PLC lifted its position in shares of Dianthus Therapeutics by 390.5% during the 3rd quarter. Barclays PLC now owns 41,684 shares of the company’s stock valued at $1,141,000 after buying an additional 33,185 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of Dianthus Therapeutics during the 3rd quarter valued at approximately $556,000. Wellington Management Group LLP purchased a new position in shares of Dianthus Therapeutics during the 3rd quarter valued at approximately $1,473,000. Finally, State Street Corp lifted its holdings in Dianthus Therapeutics by 101.4% in the 3rd quarter. State Street Corp now owns 821,131 shares of the company’s stock valued at $22,483,000 after purchasing an additional 413,425 shares in the last quarter. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently issued reports on DNTH. HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a report on Monday, November 11th. Oppenheimer upped their price objective on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a report on Monday, November 11th. Raymond James upgraded shares of Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. Finally, TD Cowen started coverage on shares of Dianthus Therapeutics in a report on Friday, December 20th. They set a “buy” rating on the stock. Eight investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Dianthus Therapeutics has an average rating of “Buy” and a consensus price target of $46.43.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.